Navigation Links
Frost & Sullivan Lauds IncellDx for Developing a Novel, Non-invasive Method for Cervical Cancer Testing

MOUNTAIN VIEW, Calif., Sept. 11, 2012 /PRNewswire/ -- Based on its recent analysis of the molecular diagnostics market, Frost & Sullivan recognizes IncellDx with the 2012 North American Frost & Sullivan Award for Product Leadership for its pioneering cervical cancer testing technology, a methodology which holds the promise of decreasing the number of unnecessary, painful, and expensive invasive testing procedures. Numerous clinical studies evaluating the company's HPV OncoTect® technology have demonstrated similar sensitivity but much greater specificity for cervical disease than traditional screening processes. Additionally, the core technology holds great promise as a diagnostic test for breast cancer, doing away with the need for more invasive surgical biopsies.

IncellDx's innovative technology aids in the analysis of intact cells using flow or image cytometry after the target protein, DNA, or RNA biomarkers within the cell are bound by labels.

"The cornerstone of IncellDx's revolutionary approach is its proprietary incellFP reagent, which allows for a one-step fixation/permeabilization," says Frost & Sullivan Global Program Manager Jennifer Brice. "The incellFP reagent fixes and permeabilizes the outer cell and nuclear membranes, permitting in situ probe hybridization without destroying prior antibody labeling of cell surface markers."

In 2011, the U.S. Preventive Services Task Force issued new cervical cancer screening recommendations that discouraged the use of human papillomavirus (HPV) screens in young women, since they are more likely to have HPV infections that clear on their own. These recommendations aimed to reduce the number of false positives thrown up by Pap and HPV tests—an issue well-addressed by IncellDx's HPV OncoTect® methodology. The technology is designed to have similar sensitivity to, but much higher specificity than, current high-risk HPV genotyping technologies.

When HPV infections progress towards cervical cancer they integrate into the patient's host genome which causes HPV E6, E7 mRNA to be over-expressed. Frost & Sullivan's competitive benchmarking reveals that IncellDx's HPV OncoTect® methodology has a unique and powerful approach to the detection and quantification of E6 and E7 mRNA inside each collected cervical cell. 

"Unlike other molecular diagnostic technologies that are limited to detecting high-risk HPV infections off of genomic material extracted from lysed cervical cells, IncellDx's patented technology is able to keep the target cervical cells intact and thereby quantify the actual E6, E7 mRNA overexpression in each and every cell," observes Brice. "Studies have shown that the HPV OncoTect® technology is much more predictive of actionable cervical disease than screening for high-risk HPV."

In the near future Frost & Sullivan expects OncoTect 3DxTM to transform the traditional Pap based cytopathology laboratory. With the addition of image cytometry, 3DxTM adds the morphological analysis routinely done in a Pap test to the molecular analysis from the OncoTect® method. Once commercially available this technology will enable laboratories to retire their microscopes for cervical cancer screening and completely digitize their cytopathology testing.

"With as many as 60 million Pap tests analyzed in the U.S. annually, IncellDx's technology could supplant an entire $2 billion Pap screening industry," observes Brice. "And in countries such as China, where the required infrastructure for widespread Pap screening does not even exist, OncoTect 3DxTM could easily become the primary approach to cervical cancer screening."

Looking forward, IncellDx can leverage its burgeoning relationships with many of the world's largest reference laboratories to ensure continued excellence in strategy and operations.

Each year, Frost & Sullivan presents this award to the company that has demonstrated innovation in product features and functionality, and that provides enhanced quality and higher value to customers. The award recognizes the rapid acceptance such innovation finds in the marketplace.

Frost & Sullivan Best Practices Awards recognize companies in a variety of regional and global markets for demonstrating outstanding achievement and superior performance in areas such as leadership, technological innovation, customer service, and strategic product development. Industry analysts compare market participants and measure performance through in-depth interviews, analysis, and extensive secondary research in order to identify best practices in the industry.

About IncellDx

IncellDx, Inc. is a molecular diagnostics company dedicated to the detection and monitoring of life threatening diseases such as cervical cancer, breast cancer, HIV/AIDs, hepatitis, and organ transplant rejection.

About Frost & Sullivan

Frost & Sullivan, the Growth Partnership Company, works in collaboration with clients to leverage visionary innovation that addresses the global challenges and related growth opportunities that will make or break today's market participants.

Our "Growth Partnership" supports clients by addressing these opportunities and incorporating two key elements driving visionary innovation: The Integrated Value Proposition and The Partnership Infrastructure.

  • The Integrated Value Proposition provides support to our clients throughout all phases of their journey to visionary innovation including: research, analysis, strategy, vision, innovation and implementation.
  • The Partnership Infrastructure is entirely unique as it constructs the foundation upon which visionary innovation becomes possible. This includes our 360 degree research, comprehensive industry coverage, career best practices as well as our global footprint of more than 40 offices.

For more than 50 years, we have been developing growth strategies for the global 1000, emerging businesses, the public sector and the investment community. Is your organization prepared for the next profound wave of industry convergence, disruptive technologies, increasing competitive intensity, Mega Trends, breakthrough best practices, changing customer dynamics and emerging economies?

Contact Us:     Start the discussion

Join Us:           Join our community

Subscribe:       Newsletter on "the next big thing"

Register:        Gain access to visionary innovation


Mireya Espinoza
P: 210. 247.3870
F: 210.348.1003

SOURCE Frost & Sullivan
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Frost & Sullivan Predicts Growth for the European Vaccines Market
2. Frost & Sullivan: Where Will Laboratory Budgets be Allocated?
3. Frost & Sullivan Acknowledges the Value Dell Healthcare and Life Sciences Brings to the Enterprise Imaging Informatics Marketplace
4. Varying Technology and Application Trends Pep up the Mature Research Antibodies Market, Finds Frost & Sullivan
5. Brazilian Healthcare Industry Thrives in Favorable Socioeconomic Environment, Finds Frost & Sullivan
6. Frost & Sullivan Lauds U-Systems for Its Unique Technology and Strategic Excellence Paving the Way for Robust Growth
7. Frost & Sullivan Recognizes Terso Solutions, Inc. with 2012 Best Practices Award
8. Frost & Sullivan Lauds MobileHelp for Its Outstanding Products and Performance in the North American Health Technology Market
9. Frost & Sullivan Recognizes Rosetta Genomics for Its Strategic Excellence and Strong Contribution to Next-Generation Diagnostics
10. Increasing Minimal Invasive Surgeries to Boost Adoption of Hybrid Operating Rooms in Europe, Says Frost & Sullivan
11. Frost & Sullivan: Improving Economies in Indonesia and Vietnam Present Strong Growth Potential in Healthcare
Post Your Comments:
(Date:9/27/2017)... for their devotion to personalized service, SMP Pharmacy Solutions announces ... the South Florida Business Journal,s 50 Fastest-Growing Companies, and listed ... national specialty pharmacy has found its niche.  To that end, ... honored by SFBJ as the 2017 Power Leader in Health ... his award in October, Bardisa said of the three achievements, ...
(Date:9/25/2017)... PROVIDENCE, R.I. , Sept. 25, 2017 /PRNewswire/ ... immunogenicity assessment, vaccine design, and immune-engineering today announced ... focused on the development of personalized therapeutic cancer ... and has provided exclusive access to enabling technologies ... MSc Eng., MBA will lead EpiVax Oncology as ...
(Date:9/22/2017)... -- AVACEN Medical (AVACEN) announced that its CE-Marked AVACEN ... with the widespread pain associated with fibromyalgia in the ... Essex, England commented, "I had difficulty ... sleep at all, tremendous pain, with every movement sending ... AVACEN 100] enough, how this has and is helping ...
Breaking Medicine Technology:
(Date:10/12/2017)... ... 12, 2017 , ... IsoComforter, Inc. ( ), one of ... innovative new design of the shoulder pad. The shoulder pad provides optimal support ... your pain while using cold therapy. By utilizing ice and water that is circulated ...
(Date:10/12/2017)... , ... October 12, 2017 , ... ... delivery system that we intend to develop to enable prevention of a major ... to severe hearing loss, especially in pediatric patients. For cisplatin, hearing loss is ...
(Date:10/12/2017)... ... October 12, 2017 , ... Leading pediatric oncology experts at ... for the 49th Congress of the International Society of Paediatric Oncology (SIOP) ... Center for Cancer and Blood Disorders at Children’s National, and Stephen P. ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... first interactive health literacy software tool, and the Cancer Patient Education Network (CPEN), ... patient education, today announce a new strategic alliance. , As CPEN’s strategic ...
(Date:10/12/2017)... ... 2017 , ... Farm Forward joins Bon Appétit ... institutions in announcing the launch of the Leadership Circle , a program ... raised for food. , Founding members of the Leadership Circle also include Airbnb’s ...
Breaking Medicine News(10 mins):